latest update:
[TrialBase DB]

trial summary · NCT07863011

Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia

A Prospective, Single-Center, Randomized, Subject-Assessor Double-Blind, Sham-Controlled, Exploratory Clinical Trial to Evaluate the Pre- and Post-Treatment Changes of HeLaXON, a Low-Dose Radiation Therapy Device, in Patients With Mild AD Dementia

Trial record from the TrialBase DB dataset, status RECRUITING, condition Alzheimer Disease, sponsored by ReadyCure Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07863011phase —enrollment 30start 2026-10-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia. A total of 30 participants will be randomly assigned in a 1:1 ratio to receive either low-dose whole-brain radiation therapy or a sham procedure using the same device. Participants in the treatment group will receive 0.04 Gy per session twice weekly for 3 weeks, for a total of 6 sessions and a cumulative dose of 0.24 Gy. Participants in the sham group will undergo the same device procedures without radiation delivery. Participants and outcome assessors will remain blinded to treatment assignment. Changes in cognitive function, dementia severity, daily functioning, and amyloid burden will be evaluated at 6 and 12 months after treatment. Safety will be assessed throughout the study. Exploratory blood biomarkers, including plasma Aβ42/40 ratio, p-tau217, and Aβ oligomer, will also be evaluated.

Source record: https://clinicaltrials.gov/study/NCT07863011

Facts

registry idNCT07863011
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionAlzheimer Disease
sponsorReadyCure Inc.
sponsor classINDUSTRY
enrollment30
start date2026-10-26
primary completion2028-03-31
completion2028-12-30
results postednot reported

Conditions

  • Alzheimer Disease

Interventions

  • HeLaXON 1X Low-Dose Radiation Therapy
  • Sham HeLaXON 1X Procedure

Countries

  • South Korea

Intervention types: DEVICE

Work with this record